Skip to main content

Advertisement

SpringerLink
Log in

The use of psychotropics in the medically ill

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Underlying medical illness may present a challenge when prescribing psychotropic medications. Diseaserelated changes in pharmacokinetics and pharmacodynamics, as well as vulnerability to side effects, polypharmacy, and potential drug interactions are all important considerations. Successful treatment of psychiatric disorders may have a beneficial impact on medical morbidity and mortality, as well as quality of life. This article reviews the relevant considerations when using psychotropic medications in six major medical populations (cardiac, cerebral vascular, pulmonary, liver, renal, and seizure disorders).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Malhotra S, Tesar GE, Franio K: The relationship between depression and cardiovascular disorders. Curr Psychiatry Rep 2000, 2:201–205.

    Article  Google Scholar 

  2. Goldman LS: Comorbid medical illness in psychiatric patients. Curr Psychiatry Rep 2000, 2:256–263.

    Article  PubMed  CAS  Google Scholar 

  3. Brown TM, Stoudemire A, Fogel BS, Moran MG: Psychopharmacology in the medical patient. In Psychiatric Care of the Medical Patient, edn 2. Edited by Stoudemire A, Fogel BS, Greenberg DB. New York: Oxford University Press; 2000:329–372. These authors offer the most up-to-date review of the psychopharmacologic considerations when prescribing psychotropics to the medically ill. They review major drug classes such as antidepressants, neuroleptics, anxiolytics, and mood stabilizers.

    Google Scholar 

  4. Wyszynski A, Wyszynski B: The cardiovascular patient. In A Case Approach to Medical-Psychiatric Practice. Washington, DC: American Psychiatric Press; 1996:1–63.

    Google Scholar 

  5. Hunt N, Stern TA: The association between intravenous haloperidol and torsade de pointes. Psychosomatics 1995, 36:541–549.

    PubMed  CAS  Google Scholar 

  6. Di Salvo TG, O’Gara PT: Torsade de pointes caused by highdose intravenous haloperidol in cardiac patients. Clin Cardiol 1995, 18:285–290.

    PubMed  Google Scholar 

  7. Jackson T, Ditmanson L, Phibbs B: Torsade de pointes and low dose haloperidol. Arch Int Med 1997, 157:2013–2015.

    Article  CAS  Google Scholar 

  8. Hulisz DT, Dasa SL, Black LD, Heiselman DE: Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 1994, 14:239–245.

    PubMed  CAS  Google Scholar 

  9. Krahenbuhl S, Ster B, Kupferschmidt H, et al.: Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 1995, 309:315–316.

    Article  PubMed  CAS  Google Scholar 

  10. Gajwani P, Pozuelo L, Tesar GE: QT prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 2000, 41:63–65.

    Article  PubMed  CAS  Google Scholar 

  11. Hale AS: A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998, 13(suppl 3):S65-S70.

    Article  PubMed  Google Scholar 

  12. Ravin DS, Levenson JW: Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997, 31:867–870.

    PubMed  CAS  Google Scholar 

  13. Joye F, Orrillard M, Marion F, et al.: Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon. Ann Fr Anesth Reanim 1999, 18:686–690.

    PubMed  CAS  Google Scholar 

  14. Gardner DM, Milliken J, Dursun SM: Olanzapine overdose. Am J Psychiatry 1999, 156:1118–1119.

    PubMed  CAS  Google Scholar 

  15. Elian AA: Fatal overdose of olanzapine. Forensic Sci Int 1998, 91:231–235.

    Article  PubMed  CAS  Google Scholar 

  16. Stephens BG, Coleman DE, Baselt RC: Olanzapine-related fatality. J Forensic Sci 1998, 43:1252–1253.

    PubMed  CAS  Google Scholar 

  17. Varma S, Achan K: Dysrhythmia associated with clozapine. Aust N Z J Psych 1999, 33:118–119.

    Article  Google Scholar 

  18. Low RA Jr, Fuller MA, Popli A: Clozapine induced atrial fibrillation [letter]. J Clin Psychopharmacology 1998, 18:170.

    Article  Google Scholar 

  19. Leo RJ, Kreeger JL, Kim KY: Cardiomyopathy associated with clozapine. Ann Pharmacother 1996, 30:603–605.

    PubMed  CAS  Google Scholar 

  20. Bandelow B, Degner D, Kreusch U, Ruther E: Myocarditis under therapy with clozapine [letter]. Schizophr Res 1995, 17:293–294.

    Article  PubMed  CAS  Google Scholar 

  21. DasGupta K, Jefferson JW: The use of lithium in the medically ill. Gen Hosp Psychiatry 1990, 12:83–97.

    Article  PubMed  CAS  Google Scholar 

  22. Kasarskis EJ, Kuo CS, Berger R, Nelson KR: Carbamazepineinduced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992, 152:186–191.

    Article  PubMed  CAS  Google Scholar 

  23. Chemerinski E, Robinson RG: The neuropsychiatry of stroke. Psychosomatics 2000, 41:5–14. An up-to-date and comprehensive review of the neuropsychiatric disorders associated with stroke. This article reviews the current epidemiologic, diagnostic, and treatment issues for poststroke depression, poststroke anxiety disorders, and other poststroke disorders.

    PubMed  CAS  Google Scholar 

  24. Lipsey JR, Robinson RG, Pearlson GD, et al.: Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984, 1:297–300.

    Article  PubMed  CAS  Google Scholar 

  25. Reding MJ, Orto LA, Winter SW, et al.: Antidepressant therapy after stroke. A double-blind trial. Arch Neurol 1986, 43:763–765.

    PubMed  CAS  Google Scholar 

  26. Andersen G, Vestergaard K, Lritzen L: Effective treatment of poststroke depression with selective serotonin reuptake inhibitor citalopram. Stroke 1994, 25:1099–1104.

    PubMed  CAS  Google Scholar 

  27. Robinson RG, Schultz SK, Castillo C, et al.: Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000, 157:351–359. This is the only double-blind placebo-controlled study comparing a TCA to a serotonergic antidepressant in poststroke depression and illustrates some surprising results that will hopefully stimulate future research on this topic. Although there were recognized limitations in the study, the fluoxetine-treated group experienced more drop out due to intolerable side effects and significantly less response rate when compared with nortriptyline.

    Article  PubMed  CAS  Google Scholar 

  28. Lazarus LW, Winemiller DR, Lingam VR, et al.: Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry 1992, 53:447–449.

    PubMed  CAS  Google Scholar 

  29. Currier MB, Murray GB, Welch CC: Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 1992, 4:140–144.

    PubMed  CAS  Google Scholar 

  30. Weiner RD, Coffey CE, and Krystal AD: Electroconvulsive therapy in the medical and neurologic patient. In Psychiatric Care of the Medical Patient, edn 2. Edited by Stoudemire A, Fogel BS, Greenberg DB. New York: Oxford University Press; 2000:419–428.

    Google Scholar 

  31. Catchlove R, Kafer E: The effects of diazepam on respiration in patients with obstructive pulmonary disease. Anesthesiology 1971, 34:14–18.

    Article  PubMed  CAS  Google Scholar 

  32. Cohn M: Hypnotics and the control of breathing: a review. Br J Clin Pharmacol 1983, 16:2455–2505.

    Google Scholar 

  33. Mitchell-Heggs P, Murphy K, Minte K: Diazepam in the treatment of dyspnea in the "pink puffer" syndrome. Q J Med 1980, 49:9–20.

    PubMed  CAS  Google Scholar 

  34. Steen S, Amaha K, Martinez L: Effect of oxazepam on respiratory response to carbon dioxide. Anesth Analg 1966, 45:455–458.

    Google Scholar 

  35. Dent M, Yernlt J, DeCoster A: A double-blind comparison of the respiratory effects of parenteral lorazepam and diazepam in patients with COPD. Curr Med Res Opin 1975, 2:611–615.

    Google Scholar 

  36. Hanley P, Powles P: Hyponotics should never be used in patients with sleep apnea. J Psychosom Res 1993, 37(suppl 1):59–65.

    Google Scholar 

  37. Gelenberg A: Buspirone: 7-year update. J Clin Psychiatry 1994, 55:222–229.

    Google Scholar 

  38. Garner S, Eldridge F, Wagner P, et al.: Buspirone: an anxiolytic drug that stimulates respiration. Am Rev Respir Dis 1989, 139:945–950.

    Google Scholar 

  39. Mendelson WB, Maczaj M, Holt J: Buspirone administration to sleep apnea patients [letter]. J Clin Psychopharmacol 1991, 11:71–72.

    Article  PubMed  CAS  Google Scholar 

  40. Craven J, Sutherland A: Buspirone for anxiety disorders in patients with severe lung disease [letter]. Lancet 1991, 338:249.

    Article  PubMed  CAS  Google Scholar 

  41. Singh MP, Despar JA, Stansbury DW, et al.: Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993, 103:800–804.

    Article  PubMed  CAS  Google Scholar 

  42. Koek RJ, Pi EH: Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 1989, 30:359–364.

    PubMed  CAS  Google Scholar 

  43. Stoppe G, Muller P, Fuchs T, Ruther E: Life-threatening allergic reaction to clozapine. Br J Psychiatry 1992, 161:259–261.

    PubMed  CAS  Google Scholar 

  44. Lieberman JA, Safferman AZ: Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992, 62:51–70.

    Article  Google Scholar 

  45. Borson S, McDonald GJ, Gayle T, et al.: Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992, 33:190–201.

    PubMed  CAS  Google Scholar 

  46. Smoller JW, Pollack MH, Systrom D, Kradin RL: Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998, 39:24–29. Although this paper has several limitations, it presents a series of cases (six retrospective, and one prospective) on the use of sertraline in patients with mild-to-severe COPD. The cases suggest that sertraline may have antidyspneic effects that warrants further systematic clinical study.

    PubMed  CAS  Google Scholar 

  47. Papp LA, Weiss JR, Greenberg HE, et al.: Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders [letter]. Am J Psychiatry 1995, 152:1531.

    PubMed  CAS  Google Scholar 

  48. Smoller JW, Simon NM, Pollack MH, et al.: Anxiety in patients with pulmonary disease: comorbidity and treatment. Sem Clin Neuropsychiatry 1991, 4:84–97.

    Google Scholar 

  49. van den Brekel AM, Harrington L: Toxic effects of theophylline csed by fluovoxamine. Can Med Assoc J 1994, 151:1289–1290.

    Google Scholar 

  50. Suter PM: Sedation during weaning from mechanical ventilation. Clin Intens Care 1994, 5(suppl 5):8–12.

    CAS  Google Scholar 

  51. Levy NB: Psychopharmacology in patients with renal failure. Int J Psychiatry in Medicine 1990, 20:325–334.

    Article  CAS  Google Scholar 

  52. Beliles KE: Psychopharmacokinetics in the medically ill. In Psychiatric Care of the Medical Patient, edn 2. Edited by Stoudemire A, Fogel BS, Greenberg DB. New York: Oxford University Press; 2000:373–394. This is an excellent, comprehensive review of the pharmacokinetic changes in medically ill patients; focusing on hepatic, renal, gastrointestinal, and cardiac considerations. The author also reviews the implications of these changes on prescribing psychotropic medications.

    Google Scholar 

  53. Blumenfield M, Levey MB, Spinowitz B, et al.: Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 1997, 27:71–80.

    Article  PubMed  CAS  Google Scholar 

  54. Joffe P, Larsen FS, Pedersen V, et al.: Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998, 54:237–242.

    Article  PubMed  CAS  Google Scholar 

  55. Green DS, Barbhaiya RH: Clinical pharmacokinetics of nefrazone. Clin Pharmacokinet 1997, 33:260–275.

    Article  Google Scholar 

  56. Troy SM, Schultz RW, Parker VD, et al.: The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994, 56:14–21.

    Article  PubMed  CAS  Google Scholar 

  57. Gitlin M: Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993, 13:276–279.

    PubMed  CAS  Google Scholar 

  58. Thomsen K, Schou M: Avoidance of lithium intoxication: advice based on knowledge about the renal lithium clearance under various circumstances. Pharmacopsychiatry 1999, 32:83–86. This is an excellent reference reviewing and summarizing what clinicians should know when prescribing lithium in order to avoid potential toxicity.

    PubMed  CAS  Google Scholar 

  59. Jefferson JW, Kalin NH: Serum lithium levels and longterm diuretic use. JAMA 1979, 241:1134–1136.

    Article  PubMed  CAS  Google Scholar 

  60. Fliser D, Franek E, Joest M, et al.: Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997, 51:1196–1204.

    Article  PubMed  CAS  Google Scholar 

  61. Shalmi M, Rasmusen H, Antorp O, Christensen S: Effect of chronic oral furosemide administration on the 24-hour cycle of lithium clearance and electrolyte excretion in humans. Eur J Clin Psychopharmacol 1990, 38:275–280.

    CAS  Google Scholar 

  62. Ragheb M: The significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol 1990, 10:350–254.

    Article  PubMed  CAS  Google Scholar 

  63. Bennett W, Aronoff G, Golper T, et al.: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, edn 3. Philadelphia: American College of Physicians; 1994.

    Google Scholar 

  64. Leipzig RM: Psychopharmacology in patients with hepatic and gastrointestinal disease. Int J Psychiatry Med 1990, 20:109–139.

    Article  PubMed  CAS  Google Scholar 

  65. Ochs HR, Greenblatt BJ, Verburg-Ochs B, Amtlas R: Clonazepam clearance on altered end cirrhosis. Am J Gastroenterol 1986, 81:80–84.

    PubMed  CAS  Google Scholar 

  66. Wilkinson GR: The effects of liver disease and aging on the disposition of the diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatr Scand 1978, 274(suppl):56–74.

    Article  CAS  Google Scholar 

  67. Ghabrial H, Desmond PV, Watson KHR, et al.: The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 1986, 30:93–97.

    Article  PubMed  CAS  Google Scholar 

  68. Schull HJ, Wilkinson GR, Johnson R, et al.: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976, 84:420–425.

    Google Scholar 

  69. Branch RA: Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease? Hepatology 1987, 7:773–776.

    Article  PubMed  CAS  Google Scholar 

  70. Assy N, Rosser BG, Grahame GR, Minuk GY: Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. Gastrointest Endosc 1999, 49:690–694.

    Article  PubMed  CAS  Google Scholar 

  71. Hammond JB, Ahmad F: Hepatic encephalopathy and role of antibenzodiazepines. Am J Ther 1998, 5:33–36.

    Article  PubMed  CAS  Google Scholar 

  72. Demuth N, Hastier P, Zermati L, et al.: Flupenthixolinduced acute hepatitis [letter]. Gastroenterol Clin Biol 1999, 23:152–153.

    PubMed  CAS  Google Scholar 

  73. Benazzi F: Risperidone-induced hepatotoxicity. Pharmacopsychiatry 1998, 31:241.

    PubMed  CAS  Google Scholar 

  74. Hummer M, Kurz M, Kurzthaler I, et al.: Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997, 17:314–317.

    Article  PubMed  CAS  Google Scholar 

  75. Bhatia SC, Banta LE, Ehrlich DW: Molindone and hepatotoxicity. Drug Intell Clin Pharm 1985, 19:744–746.

    PubMed  CAS  Google Scholar 

  76. 76.Holt RJ: Fluphenazine decanoate-induced cholestatic jndice and thrombocytopenia. Pharmacotherapy 1984, 4:227–229.

    PubMed  CAS  Google Scholar 

  77. Jones JK, Van de Carr SW, Zimmerman H, Leroy A: Hepatotoxicity associated with phenothiazine. Psychopharmacol Bull 1983, 19:24–27.

    PubMed  CAS  Google Scholar 

  78. Dincsoy HP, Saelinger DA: Haloperidol-induced chronic colostatic liver disease. Gastroenterology 1982, 83:694–700.

    PubMed  CAS  Google Scholar 

  79. Cai Q, Benson MA, Talbot TJ, et al.: Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999, 74:692–694.

    PubMed  CAS  Google Scholar 

  80. Horsmans Y, De Clercq M, Sempoux C: Venlafaxine-associated hepatitis [letter]. Ann Intern Med 1999, 130:944.

    PubMed  CAS  Google Scholar 

  81. Aranda-Michel J, Koehler A, Bejarano PA, et al.: Nefazodoneinduced liver failure: report of three cases. Ann Intern Med 1999, 130:285–288.

    PubMed  CAS  Google Scholar 

  82. Benbow SJ, Gill G: Paroxetine and hepatotoxicity. BMJ 1997, 314:1387.

    PubMed  CAS  Google Scholar 

  83. Htekeete ML, Collee I, van Lierberger H, Elewt A: Symptomatic liver injury probably related to sertraline [letter]. Gastroenterol Clin Biol 1998, 3:364–365.

    Google Scholar 

  84. Timmings P, Lamont D: Intrahepatic cholestasis associated with moclobemide leading to death [letter]. Lancet 1996, 347:762–763.

    Article  PubMed  CAS  Google Scholar 

  85. Ilan Y, Samuel D, Reynes M, Tur-Kaspa R: Hepatic failure associated with imipramine therapy. Pharmacopsychiatry 1996, 29:79–80.

    PubMed  CAS  Google Scholar 

  86. Pedersen AM, Enevoldsen HK: Nortriptyline-induced hepatic failure. Ther Drug Monit 1996, 18:100–102.

    Article  PubMed  CAS  Google Scholar 

  87. Danan G, Bernu J, Moullot X, et al.: Amitriptyline-induced fulminant hepatitis. Digestion 1984, 30:179–184.

    Article  PubMed  CAS  Google Scholar 

  88. Weinstein RP, Gosselin JY: Case report of hepatotoxicity associated with maprotiline. Can J Psychiatry 1988, 33:233–234.

    PubMed  CAS  Google Scholar 

  89. Price LH, Nelson JC, Waltrip RW: Desipramine-associated hepatitis. J Clin Psychopharm g 1993, 3:243–246.

    Google Scholar 

  90. Gomez-Gill E, Salmeron JM, Mas A: Phenelzine-induced fulminant hepatic failure [letter]. Ann Intern Med 1996, 124:692–693.

    Google Scholar 

  91. Chu AG, Gunsolly BL, Summers RW, et al.: Trazodone and liver toxicity [letter]. Ann Intern Med 1983, 99:128–129.

    PubMed  CAS  Google Scholar 

  92. Doemolis JL, Angebd P, Grage JD, et al.: Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharm 1996, 42:394–397.

    Article  Google Scholar 

  93. Krastev Z, Terziivanov D, Vlahov V, et al.: The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand 1989, 350(suppl):91–92.

    Article  CAS  Google Scholar 

  94. van Harten J, Duchier J, Devissaguet JP, et al.: Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 1993, 24:177–182.

    Article  PubMed  Google Scholar 

  95. Schenker S, Bergstrom RF, Wolen RL, Lemberger L: Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988, 44:353–359.

    Article  PubMed  CAS  Google Scholar 

  96. Ferry N, Bernard N, Cuisind G, et al.: Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundam Clin Pharmacol 1994, 8:463–473.

    Article  PubMed  CAS  Google Scholar 

  97. Messing RO, Closson RG, Simon RP: Drug-induced seizures: a 10-year experience. Neurology 1984, 34:1582–1586.

    PubMed  CAS  Google Scholar 

  98. Alldredge BK: Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999, 53(suppl 2):S68–75. This paper reviews the literature on drug-induced seizures, seizures after psychotropic drug overdose, seizures during therapeutic use of psychotropic drugs in nonepileptic patients, and seizures during use of psychotropic drugs in patients with epilepsy. The author also briefly reviews the relevant potential drug interactions between psychotropics and anti-epileptic drugs. He concludes by attempting to make some conclusions on the relative seizure-risk associated with psychotropics.

    PubMed  CAS  Google Scholar 

  99. Monaco F, Cicolin A: Interactions between anticonvulsants and psychoactive drugs. Epilepsia 1999, 40(suppl 10):S71–76.

    Article  PubMed  CAS  Google Scholar 

  100. Ellison DW, Pentel PR: Clinical features and consequences of seizures due to cyclic antidepressant overdose. Am J Emerg Med 1989, 7:5–10.

    Article  PubMed  CAS  Google Scholar 

  101. Wedin GP, Oderda GM, Klein-Schwartz W, Gorman RL: Relative toxicity of cyclic antidepressants. Ann Emerg Med 1986, 15:797–804.

    Article  PubMed  CAS  Google Scholar 

  102. Peck AW, Stern WC, Watkinson C: Incidence of seizures during treatment with tricyclic antidepressant drugs and buproprion. J Clin Psychiatry 1983, 44:197–201.

    PubMed  CAS  Google Scholar 

  103. Preskorn SH, Taft, GA: Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992, 53:160–162.

    PubMed  CAS  Google Scholar 

  104. Riddle MA, Brown N, Dzubinski P: Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 1989, 28:587–588.

    Article  PubMed  CAS  Google Scholar 

  105. Catalano G, Cooper DS, Catalano MC, Guttman JM: Pediatric sertraline overdose. Clin Neuropharmacol 1998, 21:59–61.

    PubMed  CAS  Google Scholar 

  106. Garnier R, Azoyan P, Chataigner D, Taboulet P, et al.: Acute fluvoxamine poisoning. J Int Med Res 1993, 21:197–208.

    PubMed  CAS  Google Scholar 

  107. Storrow AB: Buproprion overdose and seizure. Am J Emerg Med 1994, 12:183–184.

    Article  PubMed  CAS  Google Scholar 

  108. Harris CR, Gualtieri J, Stark G: Fatal bupropion overdose. J Toxicol Clin Toxicol 1997, 35:321–324.

    PubMed  CAS  Google Scholar 

  109. Personne M, Sjoberg G, Persson H: Citalopram overdose—review of cases treated in Swedish hospitals [published erratum appears in J Toxicol Clin Toxicol 1997, 35:577] J Toxicol Clin Toxicol 1997, 35:237–240.

    Article  PubMed  CAS  Google Scholar 

  110. Zhalkovsky B, Walker D, Bourgeouis JA: Seizure activity and enzyme elevations after venalfaxine overdose. J Clin Psychopharmacol 1997, 17:490–491.

    Article  PubMed  CAS  Google Scholar 

  111. Donner DO, Zsook S, Billow AA, et al.: A prospective safety surveillance study for Buproprion sustained-release in the treatment of depression. J Clin Psychiatry 1998, 59:366–373.

    Google Scholar 

  112. Pisani F, Spina E, Oteri G Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 1999, 40(suppl 10):S48–56.

    Article  PubMed  CAS  Google Scholar 

  113. Logothetis J: Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967, 17:869–877.

    PubMed  CAS  Google Scholar 

  114. Devinsky O, Honiegfeld G, Patin J: Clozapine-related seizures. Neurology 1991, 41:369–371.

    PubMed  CAS  Google Scholar 

  115. Masand PS, Tesar GE: Use of stimulants in the medically ill. Psychiatr Clin North Am 1996, 19:515–547.

    Article  PubMed  CAS  Google Scholar 

  116. Wyszynski AA, Wyszynski B: The HIV-infected patient. In A Case Approach to Medical-Psychiatric Practice. Washington, DC: American Psychiatric Press; 1996:213–241.

    Google Scholar 

  117. Fernandez F, Levy J: Psychopharmacology in HIV spectrum disorders. Psychiatr Clin North Am 1994, 17:135–148.

    PubMed  CAS  Google Scholar 

  118. Masand P, Pickett P, Murray G: Psychostimulants for secondary depression in medical illness. Psychosomatics 1991, 32:203–208.

    PubMed  CAS  Google Scholar 

  119. Holmes T, Sabaawi M, Fragala M: Psychostimulant suppository treatment for depression in the gravely ill [letter]. J Clin Psychiatry 1994, 55:265–266.

    PubMed  CAS  Google Scholar 

  120. Thompson D, DiMartini A: Nonenteral routes of administration for psychiatric medications. Psychosomatics 1999, 40:185–192. This useful reference does an excellent job summarizing the options available when prescribing psychotropic medications to patients who, for whatever reason, cannot receive medication by enteral means. It provides a summary of psychotropic medications available for use via rectal, intramuscular, intravenous, sublingual, and peritoneal routes.

    PubMed  CAS  Google Scholar 

  121. Cassem N: Depression. In Massachusetts General Hospital Handbook of General Hospital Psychiatry, edn 3. Edited by Cassem NH. St Louis: Mosby-Year Book; 1991, 237–268.

Download references

Author information

Author notes

  1. Michael J. Robinson MD

    Present address: Department of Psychiatry, Division of Consultation: Liason Psychiatry, Queen’s University, Connell 4 Room 2-489 76 Stuart Street, K7L 2V7, Kingston, Ontario, Canada

Authors and Affiliations

  1. Department of Psychiatry, Medical College of Virginia Hospitals/VirginiaCommonwealth University, Box 980268, 23298, Richmond, VA, USA

    Michael J. Robinson MD & James L. Levenson MD

Authors
  1. Michael J. Robinson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James L. Levenson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, M.J., Levenson, J.L. The use of psychotropics in the medically ill. Curr Psychiatry Rep 2, 247–255 (2000). https://doi.org/10.1007/s11920-996-0018-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-996-0018-y

Keywords

Search

Navigation